David Yi

David acts on equity capital markets and M&A transactions in Asia, particularly Hong Kong and mainland China.

David has worked in our Beijing and Hong Kong offices and is currently based in Shanghai.

David speaks fluent English, Mandarin and Cantonese.

Admitted to practise in Hong Kong and New York

• Advising on the dual primary listings of Hesai, KE Holdings, XPeng and Yancoal Australia on the Hong Kong Stock Exchange.

• Advising on the secondary listings of Tencent Music Enterprise, Yum China, Huazhu Hotel and Alibaba on the Hong Kong Stock Exchange.

• Advising on the primary listings of MiniMax Group, Biren Technology, Sunshine Lake Pharma, Lens Technology, IFBH Limited, Mixue Group, Marketingforce, DPC Dash, Shanghai Chicmax, Blue Moon Group, Topsports International, Shanghai Henlius Biotech, China Merchants Commercial REIT, Sisram Medical, China Resources Pharmaceutical, Dalian Wanda, YiChang HEC Pharama and New China Life on the Hong Kong Stock Exchange.

• Advising on the privatisation of YiChang HEC Pharma, Shanghai Henlius Biotech, China Agri-industries, the MGO for the shares of Dalian Port and the share buy-back offers of CK Asset and TVB.

• Advising on the follow-on offerings of 4Paradigm, Bosideng International, Zijin Mining, Yankuang Energy, China Nonferrous Mining, XPeng Inc., GCL-Poly, Bank of Communications, China Unicom, China Everbright Bank, Sinopec, Sisram Medical, YiChang HEC Pharma, Beijing Jingneng Clean Energy and CITIC.

• Advising on the convertible bond offerings of Zijin Mining and YiChang HEC Pharma.